Danaher (NYSE:DHR – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 8.350-8.550 for the period, compared to the consensus earnings per share estimate of 8.440. The company issued revenue guidance of -.
Danaher Price Performance
Shares of NYSE:DHR traded down $4.53 during trading on Wednesday, reaching $183.88. The company had a trading volume of 3,211,713 shares, compared to its average volume of 4,367,681. The firm’s fifty day moving average is $181.33 and its 200 day moving average is $205.56. The firm has a market capitalization of $130.14 billion, a PE ratio of 35.57, a price-to-earnings-growth ratio of 2.45 and a beta of 0.81. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the firm earned $1.88 EPS. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts forecast that Danaher will post 8.43 EPS for the current year.
Danaher Dividend Announcement
Wall Street Analysts Forecast Growth
DHR has been the topic of several recent research reports. HSBC cut their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Argus cut their price objective on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. Barclays cut their price objective on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Finally, Royal Bank Of Canada initiated coverage on shares of Danaher in a research report on Thursday, May 14th. They set an “outperform” rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $235.14.
Check Out Our Latest Research Report on Danaher
Institutional Investors Weigh In On Danaher
Several hedge funds have recently modified their holdings of DHR. JPL Wealth Management LLC bought a new position in Danaher in the third quarter worth $25,000. WFA of San Diego LLC bought a new position in Danaher in the second quarter worth $26,000. Transamerica Financial Advisors LLC raised its stake in Danaher by 216.3% during the fourth quarter. Transamerica Financial Advisors LLC now owns 155 shares of the conglomerate’s stock worth $36,000 after acquiring an additional 106 shares in the last quarter. Birchwood Financial Partners Inc. acquired a new position in Danaher during the fourth quarter worth $41,000. Finally, Quattro Advisors LLC acquired a new position in Danaher during the fourth quarter worth $52,000. 79.05% of the stock is owned by institutional investors.
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Read More
- Five stocks we like better than Danaher
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
